Pierre Fabre: A Long-Term Commitment to the US
Although best-known for its dermo-cosmetics, pharmaceuticals account for 50 percent of Pierre Fabre’s revenues, and the company has been engaged in cancer care for almost half a century. Now, it…
Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through the state-backed TSMC (Taiwan Semiconductor Manufacturing Company), the island functions…
Although best-known for its dermo-cosmetics, pharmaceuticals account for 50 percent of Pierre Fabre’s revenues, and the company has been engaged in cancer care for almost half a century. Now, it…
In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team…
The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its…
We need to bring together expertise in medicine, bioengineering, production technology and artificial intelligence Germany has the scientific expertise and clinical infrastructure to lead in cell and gene therapy, yet turning that strength into therapies that reach patients quickly and at scale remains a critical challenge. Dr Ulrike Köhl examines how Fraunhofer IZI is helping bridge this translational gap through…
Innovators should hold CDMOs to a high bar, and CDMOs need to step up Syed T. Husain, Chairman & CEO of Made Scientific, outlines the organization’s differentiated strategy to disrupt…
Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care…
Cell and gene therapies (CGTs) can now cure diseases that were untreatable a decade ago, often with a single dose. Yet most eligible patients – even those in rich countries…
The Middle East contains one of the world’s strongest concentrations of expertise in the rare blood disorder thalassaemia. The story starts with the high prevalence of this disease in the…
At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper,…
In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort…
After years of foundational investment in genomics, population screening, and rare disease diagnostics, Gulf nations are entering a transformative era: the delivery of advanced therapeutics. The cell and gene therapy…
With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city,…
See our Cookie Privacy Policy Here
